IOVA FY 2024 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$164M+13699.0% YoY

Gross Profit

$40M24.4% margin

Operating Income

-$395M-240.9% margin

Net Income

-$372M-226.8% margin

EPS (Diluted)

$-1.28

Cash Flow

Operating Cash Flow

-$353M

Free Cash Flow

-$364M

Stock-Based Comp.

$110M

Balance Sheet

Total Assets

$910M

Total Liabilities

$200M

Stockholders' Equity

$710M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$1M	+13699.0%
Gross Profit	$40M	-$10M	+518.9%
Operating Income	-$395M	-$461M	+14.2%
Net Income	-$372M	-$444M	+16.2%